Fasenra (benralizumab) is a prescription drug that’s used to treat conditions such as eosinophilic asthma. Fasenra is given as an injection under your skin. This drug should not be used in certain ...

FASENRA is now the only respiratory biologic that offers the choice of administration at home or in a doctor’s office with eight-week maintenance dosing WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca ...

In its heated severe asthma fight with AstraZeneca’s Fasenra, GlaxoSmithKline could take solace in the fact that its drug was more convenient for patients, with a self-administered injection option.

The National Institute for Health and Care Excellence (NICE) has recommended that a potentially life-changing treatment be available to people with a severe form of asthma on the NHS in England and ...

Dr. Michael Wechsler, Professor of Medicine and Director of The Asthma Institute at National Jewish Health, and International Coordinating Investigator of the MANDARA trial said: “This approval is ...

The Drugs Controller General of India (DCGI) has approved an injection developed by AstraZeneca for the management of patients with severe eosinophilic asthma. Called Fasenra, the injection is to be ...

Fasenra receives positive EU CHMP opinion for self-administrationand the new Fasenra pen, a pre-filled, single-use auto-injector AstraZeneca today announced that the European Medicines Agency's ...

AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the regulatory filing seeking label expansion in the EU for its blockbuster asthma ...

MISSISSAUGA, ON, Feb. 26, 2018 /CNW/ - AstraZeneca Canada today announced that Health Canada has approved Fasenra ® (benralizumab injection) as an add-on maintenance treatment for adult patients with ...

First head-to-head trial of biologics in EGPA, comparing a single monthly injection of Fasenra to three injections per month of mepolizumab Positive high-level results from the MANDARA Phase III trial ...

AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication. The regulatory body has now approved Fasenra for treating adult patients with ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated ...